FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Только для исследовательских целей. Полный disclaimer →

Исследования/Highlight the promising role of multi-receptor agonists in treating metabolic dysfunction-associated steatohepatitis and discuss their potential benefits and challenges.
Назад в Научную Библиотеку
GLP-1GIP/GLP-1GCGR/GLP-1

Highlight the promising role of multi-receptor agonists in treating metabolic dysfunction-associated steatohepatitis and discuss their potential benefits and challenges.

May 16, 2026
Share

Исходная статья

GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.

Singh Anmol et al.World journal of gastroenterology2024
Развивающиеся Исследования

Основано на развивающихся исследованиях. Эти выводы обещающи, но требуют дальнейшей проверки.

О данном анализе

Эта статья разбивает выводы из исходной статьи выше на доступный язык для сообщества исследований Peptide. Наша цель — подчеркнуть то, что наиболее важно — практические последствия, надежность доказательств и то, что это означает для текущих исследований.

Multi-Receptor Agonists Show Promise in Treating Steatohepatitis: A New Era of Peptide Therapy?

Published: May 16, 2026 | Source: World journal of gastroenterology (2024) | Category: GLP-1, GIP/GLP-1, GCGR/GLP-1

Overview

A recent review published in the World Journal of Gastroenterology highlights the potential of multi-receptor agonists like GLP-1/GIP and GCGR/GLP-1 for treating metabolic dysfunction-associated steatohepatitis (MASH). This research underscores a promising new direction in peptide therapy, with these agents showing improved efficacy over single-agent therapies while also presenting unique challenges.

Study Background

Metabolic dysfunction-associated steatotic liver disease (MASLD), which includes MASH and non-alcoholic fatty liver disease (NAFLD), affects nearly one-third of the global population. The condition is linked to increased risk of metabolic, cardiovascular, and malignant diseases, making its management a pressing issue in healthcare. GLP-1 receptor agonists have been explored for their potential benefits in managing MASH, but recent studies suggest that multi-receptor agonists may offer even greater therapeutic advantages.

What the Research Found

The review synthesizes findings from various clinical trials involving GLP-1/GIP and GCGR/GLP-1 receptor agonists. These agents were found to be more effective than single-agent GLP-1 agonists in managing MASH, showing higher rates of disease resolution and fibrosis improvement. However, the tolerability of these medications remains a concern due to gastrointestinal side effects such as nausea and diarrhea.

What This Means for Peptide Users

For patients with MASH, this research suggests that multi-receptor agonists might offer better outcomes compared to traditional single-agent therapies. However, it is crucial to weigh the benefits against potential side effects and consult healthcare providers before making any changes in treatment regimens.

Limitations and Caveats

As a review paper, this study does not present new primary data but rather synthesizes existing literature. The conclusions are thus limited by the quality and availability of previous studies. Additionally, while multi-receptor agonists show promise, their long-term efficacy and safety profiles require further investigation.

How This Compares to Previous Research

Previous research has focused primarily on single-agent GLP-1 receptor agonists for MASH management, with mixed results in terms of fibrosis improvement. The current review highlights the potential benefits of multi-receptor agonists but also emphasizes ongoing challenges related to tolerability and side effects.

Our Analysis

PeptideVault's analysis suggests that while this review offers valuable insights into the evolving landscape of MASH therapeutics, it is essential to approach its conclusions with caution due to the limitations inherent in a literature-based study. Future research should aim to address these gaps by conducting more comprehensive clinical trials and long-term studies.

Key Takeaways

  • Multi-receptor agonists like GLP-1/GIP and GCGR/GLP-1 show promise for treating MASH, offering improved efficacy over single-agent therapies.
  • Gastrointestinal side effects remain a significant concern with the use of these agents.
  • Further research is needed to optimize drug regimens and identify patient populations most likely to benefit from multi-receptor agonists.

Original Source

Citation: Singh Anmol, Sohal Aalam, Batta Akash (2024). GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.. World journal of gastroenterology. DOI: 10.3748/wjg.v30.i48.5205

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Примечание Редактора

Этот анализ был подготовлен командой исследований Peptide Contacts. Мы призываем читателей проверить полный исходный источник полная методология и данные. Исходное издание доступно на PubMed.

Связанные Исследования

Comments

Sign in to join the discussion

Этот анализ сгенерирован на основе рецензированных исследований для образовательных целей только. Это не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед использованием каких-либо терапий на основе Peptide.